These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25604244)

  • 1. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
    Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
    J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.
    Van Tubergen EA; Banerjee R; Liu M; Vander Broek R; Light E; Kuo S; Feinberg SE; Willis AL; Wolf G; Carey T; Bradford C; Prince M; Worden FP; Kirkwood KL; D'Silva NJ
    Clin Cancer Res; 2013 Mar; 19(5):1169-79. PubMed ID: 23349315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
    Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
    Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
    Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
    Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells.
    Kim JS; Lee JH; Jeong WW; Choi DH; Cha HJ; Kim DH; Kwon JK; Park SE; Park JH; Cho HR; Lee SH; Park SK; Lee BJ; Min YJ; Park JW
    Int J Cancer; 2008 Feb; 122(3):672-80. PubMed ID: 17955488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
    Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
    Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
    Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.
    Li F; Shanmugam MK; Siveen KS; Wang F; Ong TH; Loo SY; Swamy MM; Mandal S; Kumar AP; Goh BC; Kundu T; Ahn KS; Wang LZ; Hui KM; Sethi G
    Oncotarget; 2015 Mar; 6(7):5147-63. PubMed ID: 25762616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents.
    Kawakami K; Tsukuda M; Mizuno H; Nishimura G; Ishii A; Hamajima K
    Anticancer Res; 1999; 19(5B):3927-32. PubMed ID: 10628333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
    Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
    Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
    Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells.
    Huang Z; Wang L; Wang Y; Zhuo Y; Li H; Chen J; Chen W
    J Oral Pathol Med; 2013 Aug; 42(7):541-6. PubMed ID: 23413783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
    Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
    Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
    Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
    Ashimori N; Zeitlin BD; Zhang Z; Warner K; Turkienicz IM; Spalding AC; Teknos TN; Wang S; Nör JE
    Mol Cancer Ther; 2009 Apr; 8(4):893-903. PubMed ID: 19372562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
    Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
    Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
    Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.